NexImmune Analyst Ratings
NexImmune Analyst Ratings
While ratings are subjective and will change, the latest NexImmune (NEXI) rating was a downgraded with a price target of $0.00 to $0.00. The current price NexImmune (NEXI) is trading at is $0.45, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2022 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 11/15/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 08/16/2022 | 339.66% | Barclays | $7 → $2 | Maintains | Overweight |
| 08/16/2022 | 559.49% | Raymond James | $12 → $3 | Maintains | Outperform |
| 06/01/2022 | 999.14% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 04/01/2022 | 1438.8% | Barclays | $4 → $7 | Maintains | Overweight |
| 02/22/2022 | 2757.77% | Raymond James | $21 → $13 | Maintains | Outperform |
| 11/15/2021 | 4516.4% | Raymond James | $30 → $21 | Maintains | Outperform |
| 04/01/2021 | 6494.86% | Raymond James | → $30 | Initiates Coverage On | → Outperform |
| 03/09/2021 | 7594% | Cantor Fitzgerald | → $35 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行空间 | 分析师公司 | 价格目标变更 | 评级变化 | 之前/现今评级 |
|---|---|---|---|---|---|
| 11/16/2022 | — | Cantor Fitzgerald | 降级 | 过重变为中立 | |
| 11/15/2022 | — | 雷蒙德·詹姆斯 | 降级 | 强劲 → 市场表现 | |
| 08/16/2022 | 339.66% | 巴克莱银行 | $7 → $2 | 维持 | 超重 |
| 08/16/2022 | 559.49% | 雷蒙德·詹姆斯 | $12 → $3 | 维持 | 跑赢大盘 |
| 06/01/2022 | 999.14% | BTIG | → $5 | 开始覆盖 | 买入 |
| 04/01/2022 | 1438.8% | 巴克莱银行 | $4 → $7 | 维持 | 超重 |
| 02/22/2022 | 2757.77% | 雷蒙德·詹姆斯 | $21 → $13 | 维持 | 跑赢大盘 |
| 11/15/2021 | 4516.4% | 雷蒙德·詹姆斯 | $30 → $21 | 维持 | 跑赢大盘 |
| 04/01/2021 | 6494.86% | 雷蒙德·詹姆斯 | → $30 | 开始覆盖 | →买入 |
| 03/09/2021 | 7594% | Cantor Fitzgerald | →35美元 | 开始覆盖 | → 超重 |
What is the target price for NexImmune (NEXI)?
NexImmune（NEXI）的目标价是多少？
The latest price target for NexImmune (NASDAQ: NEXI) was reported by Cantor Fitzgerald on November 16, 2022. The analyst firm set a price target for $0.00 expecting NEXI to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
Cantor Fitzgerald在2022年11月16日发布了NexImmune（NASDAQ：NEXI）的最新目标价。该分析机构设定的目标价为0.00美元，预计NEXI会在12个月内下跌（可能下跌100.00%）。去年有7家分析机构发布了评级报告。
What is the most recent analyst rating for NexImmune (NEXI)?
NexImmune（NEXI）的最新分析师评级是什么？
The latest analyst rating for NexImmune (NASDAQ: NEXI) was provided by Cantor Fitzgerald, and NexImmune downgraded their neutral rating.
NexImmune（NASDAQ：NEXI）的最新分析师评级由Cantor Fitzgerald提供，NexImmune将中立评级下调了。
When is the next analyst rating going to be posted or updated for NexImmune (NEXI)?
NexImmune（NEXI）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NexImmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NexImmune was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.
分析师在做了大量研究之后才会给出股票评级，包括查看公开的基本报表，与NexImmune的高管和客户交谈，并听取业绩会通话的内容。大多数分析师每三个月就会计划进行这项研究工作，因此每年每个公司每个机构应该会得到四个评级。NexImmune的最后一个评级是在2022年11月16日提交的，因此您应该期待下一个评级的发布时间约为2023年11月16日左右。
Is the Analyst Rating NexImmune (NEXI) correct?
NexImmune（NEXI）的分析师评级是否正确？
While ratings are subjective and will change, the latest NexImmune (NEXI) rating was a downgraded with a price target of $0.00 to $0.00. The current price NexImmune (NEXI) is trading at is $0.45, which is out of the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的NexImmune（NEXI）评级是下调的，目标价为0.00美元至0.00美元。目前的NexImmune（NEXI）的股价为0.45美元，已经超出了分析师预测的区间范围。